Ming Shi, MD
Sun Yat-sen University
11
11
1
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+9 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Peng Wang, MD
Fudan University
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Saleh K Saleh, MD
Minia University
Shared therapeutic areas:
shiow-ching shun, PhD
National Taiwan University
Shared therapeutic areas:
Ping Liang, doctor
Chinese PLA General Hospital
Shared therapeutic areas:
Jieer Ying
Zhejiang Cancer Hospital
Shared therapeutic areas:
Jinbo Yue, Doctor
Shandong Cancer Hospital and Institute
Shared therapeutic areas:
yanhua Ding, MD
The First Hospital of Jilin University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
HAIC Versus Systemic Chemotherapy for Unresectable ICC
Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion
Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
All 11 trials loaded